ORPHA:728
Relapsing polychondritis
Also known as: Polychondropathia
Publications
3,233
Trials
8
Interventional, condition-specific
Researchers
1,132
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, clinically heterogeneous, multisystemic inflammatory disease characterized by inflammation of the cartilage and proteoglycan rich structures leading to cartilage damage along with joint, ocular and cardiovascular involvement.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019125
- MeSH:D011081
- UMLS:C0032453
- NCIT:C157268
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,233 matched papers (1,553 in last 10 years) Source
- Phenotype characterisedPresent
53 HPO annotations (e.g. Chondritis; Chondritis of pinna; Tinnitus) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
8 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
53
Associated phenotypes · MONDO:0019125
- Chondritis
- Chondritis of pinna
- Tinnitus
- Ataxia
- Limitation of joint mobility
Showing 5 of 53 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
8
Drugs / clinical candidates · MONDO_0019125
- ADALIMUMAB·phase 2
- ALDESLEUKIN·phase 2
- AZATHIOPRINE·phase 2
- INFLIXIMAB·phase 2
- METHOTREXATE·phase 2
- TOCILIZUMAB·phase 2
- ABATACEPT·phase 1
- UPADACITINIB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,233
3,233 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,233 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,553 in the last 10 years · low confidence
Phrase hits: 3,233 · MeSH hits: 0
Who's working on it?
1,132
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Pamfil C5 papers · 2026
Department of Rheumatology, Emergency County Clinical Hospital Cluj, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Papers in Europe PMC - 02Zhang L5 papers · 2026
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Papers in Europe PMC - 03Arnaud L4 papers · 2026
Department of Rheumatology, National Reference Center for Rare Autoimmune Diseases (RESO), INSERM UMR-S 1109, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Laurent.arnaud@chru-strasbourg.fr.
Papers in Europe PMC - 04Bucsa C4 papers · 2026
ASPOR Association of Romanian Relapsing Polychondritis Patients &, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Papers in Europe PMC - 05Crisafulli F4 papers · 2026
Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center, University of Brescia, Brescia, Italy.
Papers in Europe PMC - 06Damian L4 papers · 2026
Department of Rheumatology, Emergency County Teaching Hospital, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.
Papers in Europe PMC - 07Grayson PC4 papers · 2026
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Papers in Europe PMC - 08Mertz P4 papers · 2026
Department of Rheumatology, National Reference Center for Rare Autoimmune Diseases (RESO), INSERM UMR-S 1109, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Papers in Europe PMC - 09
- 10Zhang J4 papers · 2026
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
8 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 91.5th percentile).
low confidence · 91.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06941376·RECRUITING·An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
Not reviewed·Conditions: Relapsing Polychondritis·Matched via name phrase
- NCT06873100·RECRUITING·Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Not reviewed·Conditions: Relapsing Polychondritis·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04919538·RECRUITING·Longitudinal Study for Relapsing Polychondritis
Not reviewed·Conditions: Relapsing Polychondritis · Vasculitis·Matched via name phrase
- NCT02257866·RECRUITING·Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Not reviewed·Conditions: Takayasu's Arteritis · Giant Cell Arteritis · Polyarteritis Nodosa · Relapsing Polychondritis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- isrctn·ISRCTN13615940·Stopped·First-in-human study for the 'FibroFix Cartilage P™' knee implant
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16502655·Stopped·Biologics in refractory vasculitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55277999·No longer recruiting·In vivo isolation of circulating tumor cells from peripheral blood of patients with lung cancer by using a structured antibody-coated nanodetector
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10403616·No longer recruiting·Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetector
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Relapsing polychondritis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Relapsing polychondritis" OR "Polychondropathia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Relapsing polychondritis" OR "Polychondropathia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3233) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:04:40.792Z
